480 related articles for article (PubMed ID: 9316053)
1. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
3. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
[TBL] [Abstract][Full Text] [Related]
4. Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells.
Nitta T; Sato K
Neurosurgery; 1994 Feb; 34(2):309-14; discussion 314-5. PubMed ID: 8177392
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration.
Biro S; Fu YM; Yu ZX; Epstein SE
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):654-8. PubMed ID: 8421701
[TBL] [Abstract][Full Text] [Related]
6. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.
Chavany C; Connell Y; Neckers L
Mol Pharmacol; 1995 Oct; 48(4):738-46. PubMed ID: 7476902
[TBL] [Abstract][Full Text] [Related]
7. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.
Stewart DA; Xu X; Thomas SD; Miller DM
Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846
[TBL] [Abstract][Full Text] [Related]
8. Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation.
Stewart DA; Thomas SD; Mayfield CA; Miller DM
Nucleic Acids Res; 2001 Oct; 29(19):4052-61. PubMed ID: 11574688
[TBL] [Abstract][Full Text] [Related]
9. [An EGFR antisense oligodeoxynucleotides and its phosphorothioate analogue inhibit the growth of human hepatocarcinoma BEL-7404 cells].
Lin JQ; Xu ZS; Zhang HY; Yang ZW; Xu YH
Shi Yan Sheng Wu Xue Bao; 1995 Sep; 28(3):241-6. PubMed ID: 8571707
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer.
Watson PH; Pon RT; Shiu RP
Cancer Res; 1991 Aug; 51(15):3996-4000. PubMed ID: 1855215
[TBL] [Abstract][Full Text] [Related]
12. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides.
Jachimczak P; Hessdörfer B; Fabel-Schulte K; Wismeth C; Brysch W; Schlingensiepen KH; Bauer A; Blesch A; Bogdahn U
Int J Cancer; 1996 Jan; 65(3):332-7. PubMed ID: 8575854
[TBL] [Abstract][Full Text] [Related]
14. A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer.
Akie K; Dosaka-Akita H; Murakami A; Kawakami Y
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):243-9. PubMed ID: 10984118
[TBL] [Abstract][Full Text] [Related]
15. Rapid induction of Jak2 and Sp1 in T cells by phosphorothioate oligonucleotides.
Too CK
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):87-94. PubMed ID: 9593046
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
Uchida T; Gao JP; Wang C; Satoh T; Itoh I; Muramoto M; Hyodo T; Irie A; Akahoshi T; Jiang SX; Kameya T; Baba S
Mol Urol; 2001; 5(2):71-8. PubMed ID: 11690551
[TBL] [Abstract][Full Text] [Related]
17. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
18. Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides.
Petch AK; Sohail M; Hughes MD; Benter I; Darling J; Southern EM; Akhtar S
Biochem Pharmacol; 2003 Sep; 66(5):819-30. PubMed ID: 12948863
[TBL] [Abstract][Full Text] [Related]
19. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
20. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
Ginobbi P; Geiser TA; Ombres D; Citro G
Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
